Kwok-Kin Wong

Zitiert von

	Alle	Seit 2019
Zitate	76346	40865
h-index	141	102
i10-index	342	310

9000

4500

2250

6750

2006200720082009201020112012201320142015201620172018201920202021202220232024221 478 684 928 1479 2039 2732 3152 3757 4275 4506 4720 5004 5653 6679 8045 7615 6749 6081

Öffentlicher Zugriff

Alle anzeigen

273 Artikel

4 Artikel

verfügbar

nicht verfügbar

Basierend auf Fördermandaten

Koautoren

Pasi JanneDana Farber Cancer InstituteBestätigte E-Mail-Adresse bei dfci.harvard.edu
Takeshi ShimamuraAssociate Professor, Department of Surgery, University of Illinois at ChicagoBestätigte E-Mail-Adresse bei uic.edu
Hongbin JiInstitute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, ChineseBestätigte E-Mail-Adresse bei sibcb.ac.cn
Nathanael S. GrayProfessor of Chemical and Systems BiologyBestätigte E-Mail-Adresse bei stanford.edu
Ting ChenNYU Langone Medical CenterBestätigte E-Mail-Adresse bei nyulangone.org
Zhao ChenUniversity of ArizonaBestätigte E-Mail-Adresse bei email.arizona.edu
Chunxiao XuEMD Serono, Merck KGaABestätigte E-Mail-Adresse bei emdserono.com
Adam BassNovartis Institutes of Biomedical ResearchBestätigte E-Mail-Adresse bei novartis.com
Liang ChenProfessor of Computer Science, University of Northern British ColumbiaBestätigte E-Mail-Adresse bei unbc.ca
Norman E. SharplessFormer Director, The National Cancer InstituteBestätigte E-Mail-Adresse bei med.unc.edu
John HeymachChair, Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer CenterBestätigte E-Mail-Adresse bei mdanderson.org
Ronald A. DePinhoMD AndersonBestätigte E-Mail-Adresse bei mdanderson.org
Christine Fillmore BrainsonUniversity of KentuckyBestätigte E-Mail-Adresse bei uky.edu
Gordon FreemanDana-Farber Cancer Institute, Harvard Medical SchoolUnknown affiliationBestätigte E-Mail-Adresse bei dfci.harvard.edu
Richard S. MaserThe Jackson LaboratoryBestätigte E-Mail-Adresse bei jax.org
Scott RodigProfessor of Pathology, Brigham & Women's HospitalBestätigte E-Mail-Adresse bei bwh.harvard.edu
David BarbieDana-Farber Cancer InstituteBestätigte E-Mail-Adresse bei partners.org
Diego H. CastrillonUT SouthwesternBestätigte E-Mail-Adresse bei utsouthwestern.edu
Hua ZhangUniversity of Pittsburgh School of MedicineBestätigte E-Mail-Adresse bei pitt.edu
Susumu S. KobayashiBeth Israel Deaconess Medical CenterBestätigte E-Mail-Adresse bei bidmc.harvard.edu

Folgen

Kwok-Kin Wong

NYU Langone Health

Bestätigte E-Mail-Adresse bei nyulangone.org

lung cancer biology therapeutics preclinical models


Titel Nach Zitationen sortieren Nach Jahr sortieren Nach Titel sortieren	Zitiert von Zitiert von	Jahr
A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations SV Sharma, DY Lee, B Li, MP Quinlan, F Takahashi, S Maheswaran, ... Cell 141 (1), 69-80, 2010	2763	2010
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP CH Yun, KE Mengwasser, AV Toms, MS Woo, H Greulich, KK Wong, ... Proceedings of the National Academy of Sciences 105 (6), 2070-2075, 2008	2325	2008
Non-small-cell lung cancers: a heterogeneous set of diseases Z Chen, CM Fillmore, PS Hammerman, CF Kim, KK Wong Nature Reviews Cancer 14 (8), 535-546, 2014	1872	2014
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models D Li, L Ambrogio, T Shimamura, S Kubo, M Takahashi, LR Chirieac, ... Oncogene 27 (34), 4702-4711, 2008	1686	2008
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers JA Engelman, L Chen, X Tan, K Crosby, AR Guimaraes, R Upadhyay, ... Nature medicine 14 (12), 1351-1356, 2008	1579	2008
The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins G Lu, RE Middleton, H Sun, MV Naniong, CJ Ott, CS Mitsiades, KK Wong, ... Science 343 (6168), 305-309, 2014	1570	2014
Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints S Koyama, EA Akbay, YY Li, GS Herter-Sprie, KA Buczkowski, ... Nature communications 7 (1), 10501, 2016	1506	2016
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma F Skoulidis, ME Goldberg, DM Greenawalt, MD Hellmann, MM Awad, ... Cancer discovery 8 (7), 822-835, 2018	1354	2018
Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors EA Akbay, S Koyama, J Carretero, A Altabef, JH Tchaicha, ... Cancer discovery 3 (12), 1355-1363, 2013	1340	2013
LKB1 modulates lung cancer differentiation and metastasis H Ji, MR Ramsey, DN Hayes, C Fan, K McNamara, P Kozlowski, C Torrice, ... Nature 448 (7155), 807-810, 2007	1200	2007
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M W Zhou, D Ercan, L Chen, CH Yun, D Li, M Capelletti, AB Cortot, ... Nature 462 (7276), 1070-1074, 2009	1199	2009
A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene J Luo, MJ Emanuele, D Li, CJ Creighton, MR Schlabach, TF Westbrook, ... Cell 137 (5), 835-848, 2009	1190	2009
High-throughput oncogene mutation profiling in human cancer RK Thomas, AC Baker, RM DeBiasi, W Winckler, T LaFramboise, WM Lin, ... Nature genetics 39 (3), 347-351, 2007	1172	2007
SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas AJ Bass, H Watanabe, CH Mermel, S Yu, S Perner, RG Verhaak, SY Kim, ... Nature genetics 41 (11), 1238-1242, 2009	1088	2009
EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation W Béguelin, R Popovic, M Teater, Y Jiang, KL Bunting, M Rosen, H Shen, ... Cancer cell 23 (5), 677-692, 2013	948	2013
The dTAG system for immediate and target-specific protein degradation B Nabet, JM Roberts, DL Buckley, J Paulk, S Dastjerdi, A Yang, ... Nature chemical biology 14 (5), 431-441, 2018	845	2018
PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with EGFR and ERBB2 Mutations that Are Resistant to Gefitinib JA Engelman, K Zejnullahu, CM Gale, E Lifshits, AJ Gonzales, ... Cancer research 67 (24), 11924-11932, 2007	843	2007
Co-occurring Genomic Alterations Define Major Subsets of KRAS-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic … F Skoulidis, LA Byers, L Diao, VA Papadimitrakopoulou, P Tong, J Izzo, ... Cancer discovery 5 (8), 860-877, 2015	840	2015
Overcoming EGFR (T790M) and EGFR (C797S) resistance with mutant-selective allosteric inhibitors Y Jia, CH Yun, E Park, D Ercan, M Manuia, J Juarez, C Xu, K Rhee, ... Nature 534 (7605), 129-132, 2016	838	2016
Neutrophil elastase–mediated degradation of IRS-1 accelerates lung tumor growth AMG Houghton, DM Rzymkiewicz, H Ji, AD Gregory, EE Egea, HE Metz, ... Nature medicine 16 (2), 219-223, 2010	835	2010

Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.

Artikel 1–20

Zitate pro Jahr

Doppelte Zitate

Zusammengeführte Zitate

Koautor hinzufügenKoautoren

Folgen

Zitiert von

Koautoren